Tg Therapeutics (TGTX) Operating Margin (2016 - 2025)
Historic Operating Margin for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to 18.16%.
- Tg Therapeutics' Operating Margin rose 33400.0% to 18.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.32%, marking a year-over-year increase of 195100.0%. This contributed to the annual value of 12.74% for FY2024, which is 39100.0% up from last year.
- Per Tg Therapeutics' latest filing, its Operating Margin stood at 18.16% for Q3 2025, which was up 33400.0% from 24.69% recorded in Q2 2025.
- Over the past 5 years, Tg Therapeutics' Operating Margin peaked at 69.22% during Q3 2023, and registered a low of 96923.75% during Q4 2022.
- Over the past 5 years, Tg Therapeutics' median Operating Margin value was 277.93% (recorded in 2023), while the average stood at 8898.68%.
- In the last 5 years, Tg Therapeutics' Operating Margin skyrocketed by 2000000000bps in 2021 and then tumbled by -929191400bps in 2022.
- Tg Therapeutics' Operating Margin (Quarter) stood at 4004.61% in 2021, then crashed by -2320bps to 96923.75% in 2022, then soared by 100bps to 28.39% in 2023, then surged by 197bps to 27.68% in 2024, then crashed by -34bps to 18.16% in 2025.
- Its Operating Margin stands at 18.16% for Q3 2025, versus 24.69% for Q2 2025 and 7.13% for Q1 2025.